Founded on May 21, 1998, Precigen, Inc. is a biotechnology company headquartered in Germantown, Maryland. The company focuses on developing advanced gene and cell therapies to address critical diseases in immuno-oncology, autoimmune disorders, and infections. With a mission to advance medicine with precision, Precigen leverages proprietary and complementary technologies to create innovative treatments that serve patients worldwide.
Notable figures associated with Precigen include its President and CEO, Helen Sabzevari. The company is publicly traded on NASDAQ under the ticker PGEN and is a component of the Russell 2000 index. Precigen has achieved significant milestones, such as groundbreaking study data for PRGN in treating recurrent respiratory papillomatosis. With a revenue of $91 million in 2019 and a workforce of 600 employees, Precigen continues to make a substantial impact in the biopharmaceutical industry.
